[1] Liaw  YF.  On-treatment  outcome  prediction and adjustment during chronic hepatitis B therapy:now  and  future  Antivir  Ther,2009,14:13-22. [2] Ahn  SH,Kweon  YO,Paik  SW,et al. Telbivudine in combinatine with adefovir  versus  adefovir  monotherapy  in  HBeAg-positive,lamivudine-resistant  chronic  hepatitis  B.  Hepatol Int,2011,12:448-451. [3] 伍思国,李耀才,杨智娟,等. 拉米夫定抗乙肝转移因子和强肝胶囊治疗慢性乙型肝炎的疗效观察. 实用肝脏病杂志,2006,9(2):84-86. [4] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [5] 斯崇文. 对当前慢性乙型肝炎抗病毒治疗的看法. 中华传染病杂志,2005,23(2):73-74. [6] Liaw  YF,Leung N,Kao  JH, et al.  Asian-pacific  consensus  statement  on  the  management  of  chronic  haepatitis  B:a 2008  update.  Liver  Int,2008,2(3):263-283. [7] Zoulim  F,Buti  M,Lok  AS.  Antiviral-resistant  heaptitis  B   virus:Can  we  prevent  the  monster  from  growing. J  Viral  Hepat,2007,14(supp 1):S29-36. [8] 朱宝剑. 阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究. 中国医师进修杂志,2010,33:22-24. [9] Seifer M,Hamatake RK,Colonno RJ,et  al.  ln vitro inhibition of hepadnavirus polymerases by the triphosphates  of  BMS-200475  and lobucavir. Antimicrob Agents Chemother,1998,42:3200-3208. [10] Sherman M,Yurdayin C,Sollano J,et al Entecavir for treatment  of lamivudine-refractory,HBeAg-positive chronic hepatitis B. Gastroenterology,2006,130:2039. |